References

Why Stock Plan B^® Now?

Talking To Patients

Resource Library

Support Materials

Online Resources

References

Prescribing Information

Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet. 1998;352:428-433.

Henshaw SK. Unintended pregnancy in the United States. Family Planning Perspectives. 1998;30:24-29, 46.

Jones RK, Henshaw D, Henshaw SK. Contraceptive use among U.S. women having abortions in 2000-2001. Perspect Sex Reprod Health. 2002;34:294-303.

Dedicated emergency contraceptive pills worldwide. Available at: http://ec.princeton.edu/questions/dedicated.html. Accessed April 7, 2005.
Van Riper KK, Hellerstedt WL, Emergency Contraceptive Pills: Dispensing Practices, Knowledge and Attitudes of South Dakota Pharmacists. Perspect Sex Reprod Health. 2005: 37:19-24.

Important Safety Information

Plan B^® is indicated to prevent pregnancy following unprotected intercourse or contraceptive failure.

Plan B^® is contraindicated in women with known or suspected pregnancy, or hypersensitivity to any component of the product.

Plan B^® is not recommended for routine use as a contraceptive. Plan B^® is not effective in terminating an existing pregnancy. Plan B^® does not protect against HIV infection and other sexually transmitted infections (STIs).

Menstrual bleeding may be heavier or lighter, earlier or later after taking Plan B^®. If menses is delayed beyond one week, pregnancy should be considered. Severe abdominal pain may signal a tubal (ectopic) pregnancy.

Common side effects associated with the use of Plan B^® include nausea, abdominal pain, fatigue, headache, menstrual changes, dizziness, breast tenderness, vomiting and diarrhea.

Plan B^® is a registered trademark of Women's Capital Corporation, a subsidiary of Duramed Pharmaceuticals, Inc.

Duramed is a subsidiary of Barr Pharmaceuticals, Inc.